Signatur Biosciences’ technology expands PCR testing to a whole new range of conditions. They design smart PCR kits that can detect complex diseases as easily as a COVID test using standard qPCR machines. Their kits integrate into existing clinical workflows and ubiquitous laboratory instruments.
Their PCRchitectur technology uses the molecular machinery of PCR to condense all the work of detecting and interpreting a panel of RNA biomarkers into a single test instead of relying on complex solutions.
Spin-out is advised by Prof Dame Molly Stevens
